Core Viewpoint - Wanbang Pharmaceutical's stock closed at 40.53 yuan on November 24, with a PE ratio of 66.15 times, indicating a higher valuation compared to the industry average [1] Company Overview - Anhui Wanbang Pharmaceutical Technology Co., Ltd. operates as a comprehensive CRO specializing in pharmaceutical research and clinical research services, providing outsourced professional pharmaceutical R&D services to pharmaceutical companies and other R&D institutions [1] - The company's main products include Site Management Organization (SMO), Biological Sample Analysis (BA), Data Management and Statistical Analysis (DM/ST), Prescription Process Research, Quality Research, and Stability Research [1] Financial Performance - For the third quarter of 2025, the company reported revenue of 209 million yuan, a year-on-year decrease of 28.60%, and a net profit of 33.11 million yuan, down 57.44% year-on-year, with a gross profit margin of 30.42% [1] Market Position - The company's total market capitalization is 2.702 billion yuan, ranking 30th in the medical services industry, which has an average PE ratio of 44.32 times and a median of 60.11 times [1][2] - The stock has experienced a net outflow of 1.213 million yuan over the past five days, indicating a trend of capital outflow [1]
万邦医药收盘上涨2.35%，滚动市盈率66.15倍，总市值27.02亿元